BioToxTech Co

BioToxTech Co Enterprise Value

The Enterprise Value (EV) of BioToxTech Co (086040.KQ) as of Nov 22, 2026 is 60.01 B KRW. In the previous year, Enterprise Value (EV) was 66.88 B KRW — a change of -10.28% (lower).

Enterprise Value

60.01 BKRW

YoY

-10.28%

Last updated:

Enterprise Value (EV) of BioToxTech Co is 2025 60.01 B KRW. Enterprise Value (EV) of BioToxTech Co was 2024 66.88 B KRW. It decreases by -10.28% lower compared to the previous year.

The BioToxTech Co Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
55.21 B KRW
Jan 1, 2019
56.00 B KRW
Jan 1, 2020
40.48 B KRW
Jan 1, 2021
36.52 B KRW
Jan 1, 2022
55.03 B KRW
Jan 1, 2023
61.30 B KRW
Jan 1, 2024
66.88 B KRW
Jan 1, 2025
60.01 B KRW
The BioToxTech Co Enterprise Value history
YEAREnterprise ValueYoY
60.01 BKRW-10.28%
66.88 BKRW+9.10%
61.30 BKRW+11.39%
55.03 BKRW+50.71%
36.52 BKRW-9.79%
40.48 BKRW-27.71%
56.00 BKRW+1.42%
55.21 BKRW-2.90%
56.86 BKRW+12.84%
50.39 BKRW-19.85%
62.87 BKRW+22.65%
51.26 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Enterprise Value (EV) of BioToxTech Co is 60.01 B KRW in 2025.

Enterprise Value (EV) of BioToxTech Co changed from 66.88 B KRW to 60.01 B KRW, representing a -10.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s KRW, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' KRW varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioToxTech Co

All Key Metrics — BioToxTech Co